News Daily News Diagnosing FH in Kids and Teens Should Happen Early: In Real Life, It Varies Michael O'Riordan December 19, 2023
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Daily News Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE Michael O'Riordan July 25, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Daily News Aspirin Use Ups Risk of Anemia in Elderly Patients: ASPREE Michael O'Riordan June 22, 2023
News Daily News Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2 Michael O'Riordan June 14, 2023
News Daily News CABG and PCI Comparable in ACS Patients With Left Main CAD Michael O'Riordan June 06, 2023
News Conference News SCAI 2023 Thrombotic Risk Criteria Post-PCI for NSTE ACS Validated in New Analysis L.A. McKeown May 30, 2023
News Daily News Enough PCI ‘Versus’ CABG—Time to Focus on Understudied Groups Michael O'Riordan May 09, 2023
News Conference News ACC 2023 Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR Michael O'Riordan March 13, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Daily News For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI Michael O'Riordan February 23, 2023
News Daily News Longer-Term ASCVD Risk Assessment Best for Younger Patients Michael O'Riordan February 16, 2023
News Daily News Risk of Sports-Related Sudden Cardiac Arrest Low in Older Adults Michael O'Riordan February 09, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Features Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends Michael O'Riordan January 06, 2023